Uncategorized
As-needed aflibercept resolves persistent, recurrent fluid in eyes with neovascular AMD
As-needed aflibercept injections improved anatomic outcomes in eyes with recurrent or persistent retinal fluid associated with neovascular age-related macular degeneration, a study found.The retrospective study included 81 eyes of 78 patients with persistent or multiple recurrences of intraretinal or subretinal fluid while receiving monthly injections of Avastin (bevacizumab, Genentech) or Lucentis (ranibizumab, Genentech). Forty-five eyes had persistent fluid, and 36 eyes had multiple recurrences of fluid.